Posted by Michael Wonder on 17 Sep 2023
Highlights from the 11-14 September 2023 CHMP meeting
15 September 2023 - The EMA’s CHMP recommended nine medicines for approval at its September 2023 meeting.
The CHMP recommended granting a marketing authorisation for Ebglyss (lebrikizumab), for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents.
